Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4654)
All Articles published online
|
Publishing Process of This Article
|
Aug 6, 2022 (publication date) through Oct 8, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wang Z, Wu Q, Wang Q. Effect of celecoxib on improving depression: A systematic review and meta-analysis. World J Clin Cases 2022; 10(22): 7872-7882 [PMID: 36158469 DOI: 10.12998/wjcc.v10.i22.7872] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i22/7872.htm |
| Number | Citing Articles |
| 1 |
Sergey K. Zyryanov, Elena A. Baybulatova. Current challenges for therapy of comorbid patients: a new look at celecoxib. A review. Terapevticheskii arkhiv 2024; 96(5): 531 doi: 10.26442/00403660.2024.05.202769
|
| 2 |
Marianela Evelyn Traetta, Adriano Maia Chaves Filho, Elizabeth Toyin Akinluyi, Marie-Ève Tremblay. Microglia. Advances in Neurobiology 2024; 37: 457 doi: 10.1007/978-3-031-55529-9_26
|
| 3 |
A Halaris, A Sayed, M Hakimi, J Sinacore. Modulation of the inflammatory response exerts beneficial effects on anger in treatment-resistant bipolar depression. Journal of Affective Disorders Reports 2023; 13: 100602 doi: 10.1016/j.jadr.2023.100602
|
| 4 |
Rui Sun, Meng-Yu Tang, Dan Yang, Yan-Yi Zhang, Yi-Heng Xu, Yong Qiao, Bin Yu, Shu-Xia Cao, Hao Wang, Hui-Qian Huang, Hong Zhang, Xiao-Ming Li, Hong Lian. C3aR in the medial prefrontal cortex modulates the susceptibility to LPS-induced depressive-like behaviors through glutamatergic neuronal excitability. Progress in Neurobiology 2024; 236: 102614 doi: 10.1016/j.pneurobio.2024.102614
|
| 5 |
Monika Dominiak, Adam Gędek, Michalina Sikorska, Paweł Mierzejewski, Marcin Wojnar, Anna Z. Antosik-Wójcińska. Acetylsalicylic Acid and Mood Disorders: A Systematic Review. Pharmaceuticals 2022; 16(1): 67 doi: 10.3390/ph16010067
|
| 6 |
Yishu Yin, Ting Ju, Deyong Zeng, Fangyuan Duan, Yuanbing Zhu, Junlian Liu, Yongzhi Li, Weihong Lu. “Inflamed” depression: A review of the interactions between depression and inflammation and current anti-inflammatory strategies for depression. Pharmacological Research 2024; 207: 107322 doi: 10.1016/j.phrs.2024.107322
|
| 7 |
Urszula Bąk, Anna Krupa. Challenges and Opportunities for Celecoxib Repurposing. Pharmaceutical Research 2023; 40(10): 2329 doi: 10.1007/s11095-023-03571-4
|
| 8 |
Ashish Verma, Anmol Kumar, Satendra Chauhan, Nisha Sharma, Anuradha Kalani, Prakash Chandra Gupta. Interconnections of screen time with neuroinflammation. Molecular and Cellular Biochemistry 2024; doi: 10.1007/s11010-024-05123-9
|
| 9 |
Xenia Gonda, Gianluca Serafini, Peter Dome. Fight the Fire: Association of Cytokine Genomic Markers and Suicidal Behavior May Pave the Way for Future Therapies. Journal of Personalized Medicine 2023; 13(7): 1078 doi: 10.3390/jpm13071078
|
| 10 |
Bárbara Dicarlo Costa Braga, Bruna Teixeira da Costa, Katiene Rodrigues Menezes de Azevedo. Tratamento anti-inflamatório na depressão: uma revisão sistemática. Debates em Psiquiatria 2024; 14: 1 doi: 10.25118/2763-9037.2024.v14.1156
|
| 11 |
Erhan Kavakbasi, Emma Sampson, Natalie T. Mills, Hikaru Hori, Kathrin Schwarte, Christa Hohoff, K. Oliver Schubert, Scott R. Clark, Célia Fourrier, Bernhard T. Baune. Inflammation‐stratified augmentation of vortioxetine with celecoxib: Results from a double‐blind, randomized, placebo‐controlled trial in major depressive disorder. Journal of Neurochemistry 2023; doi: 10.1111/jnc.15946
|
| 12 |
Adam Gędek, Zofia Szular, Anna Z. Antosik, Paweł Mierzejewski, Monika Dominiak. Celecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine 2023; 12(10): 3497 doi: 10.3390/jcm12103497
|
| 13 |
Cheng-gang Li, Lu-shan Xu, Liang Sun, Yu-hao Xu, Xiang Cao, Chen-chen Zhao, Sheng-nan Xia, Qing-xiu Zhang, Yun Xu. Xiangshao Granules Ameliorate Post-Stroke Depression by Inhibiting Activation of Microglia and IDO1 Expression in Hippocampus and Prefrontal Cortex. Chinese Journal of Integrative Medicine 2024; doi: 10.1007/s11655-024-3903-5
|
| 14 |
Ana Salomé Correia, Nuno Vale. Advancements Exploring Major Depressive Disorder: Insights on Oxidative Stress, Serotonin Metabolism, BDNF, HPA Axis Dysfunction, and Pharmacotherapy Advances. International Journal of Translational Medicine 2024; 4(1): 176 doi: 10.3390/ijtm4010010
|
| 15 |
Mohammad M Khan, Zaw Ali Khan, Mohsin Ali Khan. Metabolic complications of psychotropic medications in psychiatric disorders: Emerging role of <i>de novo</i> lipogenesis and therapeutic consideration. World Journal of Psychiatry 2024; 14(6): 767-783 doi: 10.5498/wjp.v14.i6.767
|
| 16 |
Marcel Bertsch-Gout, Anthony T. Reder, Royce Lee. Stress: Immunology and Inflammation. 2024; : 147 doi: 10.1016/B978-0-12-817558-3.00017-2
|
| 17 |
Sahar Ansari, Hossein Sanjari Moghaddam, Fatemeh A. Basti, Mohammadreza Salehi, Shahin Akhondzadeh. Efficacy and safety of celecoxib monotherapy for treatment of moderate depressive symptoms following COVID-19 infection: A randomized, double-blind, placebo-controlled trial. Journal of Psychosomatic Research 2023; 174: 111471 doi: 10.1016/j.jpsychores.2023.111471
|
| 18 |
Bruna R. Kouba, Laura de Araujo Borba, Pedro Borges de Souza, Joana Gil-Mohapel, Ana Lúcia S. Rodrigues. Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets. Cells 2024; 13(5): 423 doi: 10.3390/cells13050423
|